CCA
JAZZ icon

Column Capital Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Column Capital Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-14
Closed -$1K – 769
2020
Q2 		$1K Buy
+14
New +$1.55K ﹤0.01% 748

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Column Capital Advisors's JAZZ Position: Q3 2020 in Review

Column Capital Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2020, closing a stake of 14 shares — an estimated $1K sold.

Column Capital Advisors first reported a position in JAZZ in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 389 funds tracked by Wall St. Rank hold JAZZ as of Q3 2020.

  • Column Capital Advisors reported no remaining Jazz Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Column Capital Advisors sold 14 Jazz Pharmaceuticals shares in Q3 2020, an estimated $1K.
  • Column Capital Advisors first reported a position in Jazz Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Column Capital Advisors's Jazz Pharmaceuticals position peaked at $1K in Q2 2020.
  • 389 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2020.

Based on Column Capital Advisors's 13F filing for Q3 2020, filed 12 Nov 2020.